THE LATEST FROM RAKOVINA
Discovery in motion.
Rakovina Therapeutics and Variational Al Strengthen Partnership
DOWNLOAD Strategic Funding Led by Nimbus Synergies, Backed by Merck GHI, to Accelerate Al-Powered Collaborations VANCOUVER, British Columbia, Feb. 26, 2025 -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies...
Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program
Vancouver, British Columbia, Feb 6, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, announces continued advancement of its AI-driven drug discovery program....
Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange
VANCOUVER, British Columbia, Jan. 30, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce that its common shares are now listed...
Rakovina Therapeutics to Participate in BioInnovate UBC Annual Conference
January 29, 2025 – Vancouver, British Columbia – Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced its participation in the...
Rakovina Therapeutics Comments on $500 Billion AI Infrastructure Investment and Its Implications for Healthcare Innovation
Vancouver, British Columbia, January 22, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company at the forefront of AI-driven drug discovery, yesterday commented on the announcement of a $500 billion private-sector investment into AI...
Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI
VANCOUVER, British Columbia, Jan. 13, 2025 -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the successful achievement of a...
Rakovina Therapeutics Announces Receipt of AI-Derived Drug Candidates and Advancement to Preclinical Validation
VANCOUVER, British Columbia, Jan. 06, 2025 -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel DNA-damage response technologies, announces the successful synthesis of novel...
Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week
VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics, Inc. (TSX: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel DNA-damage response technologies, is pleased to announce its...
Reflecting on 2024 Success and Building Momentum for a Transformative 2025
DOWNLOAD December 18, 2024, Vancouver, British Columbia /CNW/ -- Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel DNA-damage response technologies, is...
Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations
DOWNLOAD December 17, 2024, Vancouver, British Columbia /CNW/ -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) announces that in accordance with the terms of an indenture entered into between the Company and Odyssey Trust Company (“Odyssey”)...
Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement
DOWNLOAD For Immediate Release Vancouver, British Columbia, December 13, 2024-- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”, “Rakovina”, or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel...
Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million
DOWNLOAD For Immediate Release Vancouver, British Columbia, December 2, 2024 – Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response...
